Pfizer (PFE) announced today that the U.S. Food and Drug Administration
has accepted Pfizer's filing for standard review of axitinib for patients with
advanced renal cell carcinoma. This submission was based on Phase 3 data
from the AXIS 1032 trial, comparing axitinib with sorafenib in patients with
previously treated advanced RCC, which Pfizer recently presented at the 47th
Annual Meeting of the American Society of Clinical Oncology.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in